1 Running title:

3

6

10

16

- 2 Value of Venezuelan Olfactory test in SARS-CoV-2 infection
- 4 TYPE OF ARTICLE
- 5 ORIGINAL CONTRIBUTION
- 7 What do we know about smell and taste dysfunction by SARS-CoV-2. Predictive
- 8 Value of the Venezuelan Olfactory test and RT-PCR analysis in viral infection
- 9 diagnosis
- Rosalinda Pieruzzini\*<sup>1</sup>, Carlos Ayala-Grosso\*<sup>2</sup>, Jose de Jesus Navas<sup>3</sup>, Wilneg Rodríguez<sup>1</sup>, Nathalia Parra<sup>1</sup>, Emily Luque <sup>1</sup>, Aida Sánchez-Gago <sup>1</sup>, Scarleth 11
- 12
- González<sup>1</sup>, Alexandra Hagobian<sup>1</sup>, Angeline Grullón<sup>1</sup>, Karen Díaz<sup>1</sup>, Mariano Morales<sup>1</sup>, 13
- Melanie De Jesús<sup>1</sup>, Sonia Peña<sup>1</sup>, Luis Rodríguez<sup>1</sup>, Luis L Peña<sup>4</sup>, Ana Asaro<sup>5</sup>, Magda 14
- Magris<sup>6</sup> 15
- 17 1. Department of Otorhinolaryngology. University Military Hospital "Dr. Carlos Arvelo".
- 18 Neurorhinology Unit. San Martín- Caracas-Venezuela
- 19 2. Unit of Cellular Therapy, Centre of Experimental Medicine, Instituto Venezolano de Investigaciones
- 20 Científicas (IVIC). Caracas, Venezuela.
- 21 3. Direction of General Health, Fuerzas Armadas Nacional Bolivariana. Caracas-Venezuela.
- 22 4. Hospital "Dr. José María Vargas". Instituto Venezolano de los Seguros Sociales. La Guaira-
- 23 Venezuela
- 24 5. University Military Hospital "Nelson Sayago Mora". La Asuncion. Nueva Esparta-Venezuela
- 25 6. Ministry of Popular Power for Health. Caracas-Venezuela
- 26 **SUMMARY**

- 28 Background: Smell and taste disorders are reported very frequently and at an early
- 29 stage in the evolution of the infectious disease caused by the SARS-CoV-2. These
- 30 symptoms could be sensitive and specific to establish the condition of the infection,
- 31 and may suggest the flow of decisions as to further therapy. We asked whether smell
- 32 and taste impairment are earlier and more sensitive symptoms than the RT-PCR
- 33 molecular assays for SARS-CoV-2 detection.
- 34 **Methodology:** Subjects (N=275) with a probable COVID19 diagnosis were classified
- 35 as follows: Symptomatic with chemosensory dysfunction, symptomatic without
- 36 chemosensory dysfunction, and asymptomatic. Subjects received a general clinical
- 37 and otorhinolaryngology examination. Evaluation of the chemosensory dysfunction

- 38 was performed by means of the Venezuelan Olfactory Test and taste test. Nasal swabs
- 39 and blood samples were analyzed by real-time polymerase chain reaction analysis
- 40 (RT-PCR) and a rapid diagnostic test to detect the SARS-CoV-2 virus and antiviral
- 41 antibodies, respectively. Patients had access to molecular tests and smell and taste
- 42 evaluations every 3 to 5 days until they recovered.
- 43 **Results:** Out of 44 patients that were positive for RT-PCR SARS-CoV-2: 45.83%
- 44 had smell and taste disorders and COVID19 symptoms, 23.61% did not have smell or
- 45 taste disorders, but had COVID19 symptoms, and 30.55% were asymptomatic. Mild
- 46 hyposmia and hypogeusia account for the most frequent chemosensory disorders
- 47 accompanying common SARS-CoV-2 symptoms. Time to recover from the
- 48 chemosensory dysfunction ranges from 3 to 14 days, up to a maximum of 5 weeks,
- 49 while RT-PCR becomes negative after 21 days and up to 35 days in some cases. The
- Venezuelan Olfactory Test and taste test has a 61.68% positive predictive value,
- 51 45.83% sensitivity, and 68.7% specificity for SARS-CoV-2 infection.
- 52 *Conclusions*: Smell and taste disorders are frequent symptoms of SARS-CoV-2
- 53 infection, but not a significant predictor of the disease, as compared to the molecular
- 54 RT-PCR test.

55

- 56 Key words: COVID19, Smell, Taste, diagnosis, RT-PCR, olfactory test
- 58 INTRODUCTION
- 59 At the early stages of the SARS-CoV-2 infection, the smell and taste disorders seem
- 60 to have some predictive value as to the evolution of the infection (1). Since the
- 61 beginning of the pandemic, multiple studies have reported a very variable association
- 62 between the smell and taste dysfunction and the presence of other symptoms that are
- characteristic of the coronavirus infection (1).
- 64 The first reports of a multicenter study that grouped clinical data from 12 hospitals, a
- 65 population of 417 patients with mild to moderate COVID-19, list cough, myalgia and
- loss of appetite as the most common symptoms; while symptoms associated with
- otorhinolaryngology-related disorders were facial pain and nasal obstruction in at
- least 86% of the cases; and there were smell and taste disorders in 88% of the cases.
- 69 The onset of the smell dysfunction was earlier than any other symptom in 11.8% of
- 70 the cases (2).
- 71 The sudden loss of the sense of smell associated with an increasing number of cases

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

of coronavirus was reported in the United Kingdom recently; however, the evidence seems to be circumstantial, because it was found as information provided in social media by subjects who had had this symptom in an isolated fashion. The authors reported 9 cases of sudden anosmia without other associated symptoms in the first 3 weeks of the onset of the coronavirus. It is worth mentioning that none of these patients was evaluated with a specific test to determine the presence of the disorder (3). More recently, another study carried out at Hospital L. Sacco in Milan, Italy with 59 of the 88 patients of the hospital, established that 33.9% had at least one smell and/or taste disorder and 18.6% had both. In this group of patients, 20.3% had smell symptoms before they were admitted to the hospital and 13.5% during their stay (4). The presence of smell alterations associated with a viral infection is not new in otorhinolaryngology; many viruses may cause olfactory dysfunction due to an inflammatory process of the nasal mucosa and the development of rhinorrhea. Among the viral agents associated with these alterations are rhinovirus, parainfluenza, Epstein-Bar, and some coronavirus (4,5). However, the fact that olfactory dysfunction associated with SARS-CoV-2 is not essentially related to the onset of rhinorrhea and nasal obstruction suggests a different action mechanism. So far, the physiopathology of smell and taste disorders in the SARS-CoV-2 infection is still under scrutiny. One of the most relevant evidences of the action mechanism of coronavirus was reported as a result of an investigation of the olfactory mucosa of mice and analysis of RNA sequences of humans. It found that the 2 genes that express the information for angiotensin-converting enzyme 2 (ACE2) and the host transmembrane serine protease family member II (TMPRSS2) receptors involved in the entry of COV-2 into the cell are expressed in the cells of the respiratory epithelium of the nasal cavity, support cells, Bowman's glands, microvilli, and stem cells of the olfactory mucosa, but not in the olfactory sensory neurons. This suggests that the olfactory damage mechanism is non-neural in nature. As to the damage to the sense of taste, it appears to be directly on the taste receptor and as the result of the production of cytokines that irritate the trigeminal and glossopharyngeal nerves that transmit sensory signals to the central nervous system (6). Netland et al. found that, in certain transgenic mice, there was an extensive replication of the virus in the brain, with certain regional differences, and that this brain infection, in turn, was an important factor in the aspiration pneumonia seen in some of the mice

studied. A generalized neuronal infection appeared after intranasal inoculation, which

suggests that the entryway for the infection could be through the olfactory bulb. This

raises questions about the possible effects of coronavirus on patients infected with

#### Pieruzzini et al., 20201125

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

SARS-CoV-2 in the future (7). A vast majority of initial reports on smell and taste dysfunction related to coronavirus infection were based on results from patient surveys, without corroborating the diagnosis through psychophysical evaluation of chemosensory dysfunction. Patients were not followed up systematically until recovery, nor was the relationship proven by means of diagnostic tests, such as the SARS-CoV-2 RT-PCR test, or rapid diagnostic tests. These factors may have led to an overestimation of the symptom as predictive factor of the disease. Similarly, using the smell test without adjusting it to the population under analysis could result in some false positives and, consequently, an overestimation of chemosensory dysfunction diagnostics. All of the above motivated us to carry out an investigation the distinctive nature and main objective of which was to determine the predictive value of smell and taste tests in the diagnosis of SARS-CoV-2 infection, and its relationship with other diagnostic tests, such as SARS-CoV-2 RT-PCR test and the rapid diagnostic test, as well as the follow up and comprehensive observation of the patient's recovery from the coronavirus infection. The objective of this study is to determine whether smell and taste disorders are an early and more sensitive biomarker than the RT-PCR test for diagnosing the SARS-CoV-2infection. MATERIALS AND METHODS **Population** A sample of 275 individuals was selected from a population of 525 subjects examined between March and August 2020 (Table 1). The following were collected for all subjects at the beginning of the study protocol: 1. Full clinical record, including age, gender, epidemiologic background on the basis of travel and contact with positive cases, questions about suggestive respiratory signs and other symptoms, presence or not of smell and/or taste disorders. 2. General otorhinolaryngology (ORL) physical examination, Venezuelan Olfactory Test (VOT), and Basic Taste Test evaluation . 3. Nasopharyngeal swab for SARS-CoV-2 by RT-PCR molecular analysis and detection of SARS-CoV-2 antibodies by rapid diagnostic test (RDT). In this study, patients were followed-up every 3 to 5 days, to verify their overall clinical condition. In addition, smell and taste tests were carried out, blood samples

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

were drawn to perform RDTs, and nasopharyngeal swabs for RT-PCR tests, until they met the recovery criterion. The recovery criterion is met when one of the following conditions is fulfilled: 1.-The relative smell and taste test score is at the highest level and the RT-PCR test is negative. 2. - It has been established that there is no permanent smell or taste disorder. Clinical assessment The clinical assessment of patients with probable COVID19 diagnostic followed the guideline suggested by the National Institute of Health of the United States of America (NIH-USA SARS-CoV-2 assessment guidelines). The level of organ compromise is defined as mild or moderate if individuals present with fever, cough, sore throat, general malaise, headache, myalgia, anosmia, ageusia, and diarrhea. When it is a *mild* condition, patients do not complain of shortness of breath, have more than 94% oxygen saturation, and there is no clinical evidence of respiratory disease, while in the *Moderate* there is clinical and imaging evidence of mild respiratory disease. The condition is defined as *Severe* in individuals with less than 94% oxygen saturation and respiratory rate at 30 respirations per minute in adults, in addition to more than 50% pulmonary infiltrates or a PaO2/FIO2 ratio lower than 300 mmHg. In the case of *Critical* disease, there is respiratory distress which requires mechanic ventilation, as well as multiple organ failure, septic shock and vasopressor treatment. Venezuelan Olfactory Test (VOT) and Taste Test The VOT is a smell test that was adapted for Venezuela from the smell identification test of the University of Pennsylvania (UPSIT) (8). The Venezuelan short test is composed of 2 notebooks with 10 odorants that are commonly recognized by Venezuelans and which were validated during a prior exploratory study (9, 10). The substances are coffee, chocolate, baby cologne, scented talc, liquid detergent, coconut essence, powdered detergent, cinnamon, acetone, and rum. Every time an odorant is examined, the subject must identify the respective smell and discriminate it among the other substances offered and mentioned in addition to the odorant he is expected to identify. On the basis of identification and discrimination of odors presented to patients, the VOT provides a relative grading scale as follows: Normosmia (8-10), mild hyposmia (6-7), moderate hyposmia (5-4), severe hyposmia (2-3), and anosmia (0-1).

The taste test consists in recognizing the 5 universally accepted basic tastes, to wit:

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

sweet, salty, sour, bitter, and umami (11). One (1) cc of a sample of each taste is placed on the anterior third of the tongue of the patient who has his eyes closed, and after 10 seconds of period, an identification of the sample may occur. If the patient cannot recognize the tastes, he is diagnosed with ageusia, and hypogeusia if the patient recognized up to 4 tastes. Rapid Diagnostic Test (RDT) to Determine Antibodies Generated to SARS-COV-2 virus antigens Diagnostic tests No IFU-COVID3-01 (Nhui deep blue Medical Technology co. Batch: 20200307) were used to determine IgG/IgM antibodies. This kit uses a recombinant SARS-CoV-2 antigen conjugated with colloidal gold, which can interact with antibodies circulating in blood or in a serum or plasma preparation. The sample is placed on a nitrocellulose (NC) membrane that has been prepared with rat anti-IgM antibodies and human IgG antibodies, and sheep anti-rat polyclonal antibodies. When the sample diffuses in the membrane it may interact with the IgM antibodies adsorbed in it and an aggregate is produced with the coronavirus antigen marked with colloidal gold. This, in turn, is captured by the rat anti-IgM and produces a colored line. If the sample contains IgG antibodies, it forms a compound with the antigen marked with colloidal gold, this compound is captured by the rat anti-human IgG antibody and produces a colored line. When samples contain IgM and IgG at the same time, there will be 2 lines. When there are no IgM or IgG antibodies in the sample, there is only the quality control line and the result is negative. Sample Collection for RT-PCR Testing for SARS-CoV-2 detection Samples were obtained from patients by nasopharyngeal swab strictly following the biosecurity protocol. Then, they were placed in YOCON viral transport medium, batch Y25200101, and kept at a temperature between 2 and 8°C until they reached the reference laboratory. Samples collected for RT-PCR testing for SARS-CoV-2 detection were processed by the Virology Service of the "Rafael Rangel" National Hygiene Institute of the Ministry of the People's Power for Health in Caracas, Venezuela. Ethical Approval Collection and analysis of data were approved by the Bioethical committee of the "Carlos Arvelo" University Military Hospital of Caracas. All studies were conducted in compliance with the Declaration of Helsinki, and all participants signed an informed consent. The current study included participants for which there was full

208

209

210

211

212

213

214

215

216

217

218

219220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

information on multiple SARS-CoV-2 measures and key outcomes, including psychosocial factors, chronic medical conditions, and socio-demographic factors. Statistical Analysis Descriptive statistics was used in the analysis by age group and type of chemosensory impairment. The predictive value, sensitivity and specificity of diagnostic tests used were calculated on the basis of the Wilson score method using the OpenEpi, version 3 software. Diagnostic Test Open code Calculator.  $X^2$ -Square tests were used to find the most frequent type of symptom in the SARS-CoV-2 infection. We asked whether there is a relationship between the SARS-CoV-2 infection and the presence or absence of symptoms; and to evaluate the relationship among type of olfactory disorder, age and gender. In the case of the association between two variables, when the result of the  $X^2$ -Square test was positive, that is to say, the variables were dependent on, or associated to one another, a standardized residuals analysis was carried out. This analysis allows to determine in a significant manner which cell or frequency contributed more to the rejection of the null hypothesis in the  $X^2$ -Square test. Additionally, it allows to find out which cells deviated significantly from the expected value. Any deviation value higher than  $\pm 1.96$ from the normal distribution is considered significant. Pearson's  $X^2$ -Square test and Fisher's exact test were used to evaluate between-group differences in two categorical variables.  $X^2$ -Square tests and standardized residuals analyses were carried out in R with the chisq.test function of the stats. package (12). RESULTS The most frequent age group among study subjects was the 25 - 38 years old, and there were more male (54.90 %) than female (45.09 %) subjects; average age of the population was  $33.63 \pm 5$  years old (Table 2). In Venezuela, the first possible SARS-CoV-2 infection cases were reported in March (Figure 1). Initially, the disease was observed in a group of 28 patients with smell and taste disorders, although only 1 of them was confirmed positive for SARS-CoV-2 by means of the RT-PCR test. Then, starting in May, the number of individuals positive for SARS-CoV-2 was increasing in parallel with the onset of smell and taste disorders; and finally, in the month of August, a significant number of patients with smell and taste disorders also tested positive for coronavirus infection by means of the RT-PCR test.

The observation of a higher incidence of olfactory and taste disorders together with a

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263264

265

266

267

268

269

270

271

272

273

274

275

positive molecular diagnostic suggested that the dysfunction of these senses could happen before or to a greater extent than the expression of viral genes evidenced by the RT-PCR test, and this could imply that the physiology of the chemosensory system is more susceptible to SARS-CoV-2 infection. To assess this observation, molecular tests were performed on the 275 subjects who had gotten smell and taste tests. It was found that 144 subjects were RT-PCR+ for SARS-CoV-2 while 131 were RT-PCR- for SARS-CoV-2. In the RT-PCR+ group, there were more SyMVOTT+ (66/144; 45.83%) subjects than SyMVOTT- (34/144; 23.61%) or ASYM (44/144; 30.55%). In contrast, among the 131 patients that tested negative for SARS-CoV-2 in the RT-PCR test, there were more SyMVOTT+ (41/131; 31.30%) subjects than SyMVOTT- (27/131; 20.61%), but less than the ASYM (63/131; 48.10%) (Table 3). These results suggest that there are more individuals with olfactory and taste disorders among the COVID19 symptomatic population. The higher number of RT-PCR+ patients with and without olfactory and taste disorders, and with symptoms of the infection indicates that the relative effectiveness of RT-PCR tests in confirming the COVID19 infection is 75%. In contrast, if the large number of PDR- (197/275; 71.63%) individuals in the whole sample is taken into account, the relative effectiveness of this test is 28%. (Table 3). This confirms the little reliability of PDR tests for diagnosing coronavirus infection. The frequency of subjects in the SyMVOTT+, SyMVOTT- and ASYM groups as a function of the presence of chemosensory symptoms and the positive molecular test results was heterogeneous ( $X^2 = 9.19$ , gl = 2, p < 0.05), which suggests that the type of symptoms and their association with chemosensory dysfunction is different in the case of SARS-CoV-2 infection. This is consistent with what was observed in the analysis of standardized residuals, since, in the SARS-CoV-2 infection, the chemosensory dysfunction is very frequent and, in this sample, very few subjects that presented with the disease were asymptomatic (Table 4.1, Figure 1). On the other hand, olfactory and taste disorders are infrequent in the general population (Tables 3 and 3.1). Predictive Value of VOTT When the frequency of patients with olfactory and taste disorders that were diagnosed with the VOTT was compared to the RT-PCR tests positive results, the positive predictive value of the VOTT was 61.68%, while the negative predictive value was 53.57%. These results suggested that VOTT+ patients had a 0.62 probability of being

276

277

281

287

291

292

293

301

RT-PCR+ for SARS-CoV-2. On the other hand, the sensitivity and specificity for COVID-19 diagnosis of the Venezuelan Olfactory Test and basic taste test was 278 45.83% and 68.7%, respectively (Table 4). These findings supported that these tests 279 allow to detect olfactory and taste disorders in 46% of healthy individuals and in 69% 280 of patients who were also clinically SARS-CoV-2 positive. SARS-CoV-2 Affectation and Chemosensory dysfunction 282 Coronavirus infection produces different degrees of affectation, as described in the 283 methods. In this research, it was observed that 98.48 % of the 66 subjects (65/66) with 284 chemosensory impairment (VOTT+) had mild clinical signs and 1.51% (1/66) 285 moderate signs (Table 5). 286 Characteristics of VOTT+, SyVOTT+, and SyVOTT- Patients Clinical signs as a consequence of SARS-CoV-2 infection are quite variable. The 288 number of SARS-CoV-2 infected patients presenting with chemosensory disorder 289 only (VOTT+) was 18/97 (18.55%). In contrast, there were 48/97 (49.5%) SyVOTT+ 290 according to standardized residuals analysis P < 0.05; (Table 6). The group of VOTT+ patients without any other accompanying symptom (no concomitants), who referred olfactory and taste disorder as their only symptom before the molecular diagnostic and before being admitted to the hospital was 18/97 294 (18.55%) (Table 7). When differentiated on the basis of the type of chemosensory 295 dysfunction, 7 presented with olfactory disorder only, 4 of them anosmia, and 3 with 296 mild hyposmia. Combined smell and taste disorders at various degrees were present in 297 10 subjects, and only 1 had hypogeusia. All these findings suggest a disorder 298 variability that may indicate the presence of coronavirus infection and not only the 299 anosmia or the ageusia. In this group of patients, chemosensory disorders were an 300 early biomarker of the coronavirus disease. Chemosensory dysfunction was a symptom in 31.25% of the subjects of the 302 SyVOTT+ group before being admitted to the hospital. In contrast, 68.75% of the 303 patients of the sample that did not declare the disorder before being admitted to the 304 hospital, were positive for olfactory or taste disorder when the VOT and taste test 305 were used. This confirms the need to use a standardized objective taste for detecting 306 the chemosensory disorder during the hospital stay. On the other hand, the onset of the chemosensory dysfunction in the SyVOTT+ group occurred between the 3<sup>rd</sup> and 307 308 5<sup>th</sup> day in 70% of the cases.

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

Other associated symptoms in the SyVOTT+ group vary. Among them, headache, myalgia, arthralgia, shivering, odynophagia, and hyporexia in 48% of patients; fever, headache, and general malaise in 31%, dry cough and chest pain in 8% dyspnea, and only fever or myalgia in 8% and 2%, respectively. Similarly, in the SyVOTT- patients, which accounted for 32.98% of the sample, there was fever, headache, myalgia, arthralgia, and shivering in 46.87% of them; headache, arthralgia and myalgia in 15%, as well as chest pain, dyspnea in 15%, rhinorrhea, fever, nasal congestion, and dysphonia in 12.5%; and cough, general malaise, fever, and shivering in 9%. As relates the variety of symptoms in SyVOTT+ and SyVOTTgroups, no differences were observed in the frequency of presentation that would warrant an additional classification in the SARS-CoV-2 infection. Age, Gender and VOTT In this study, when the presence of chemosensory dysfunction in the subjects of the sample was taken into account, the frequency was similar among them regardless gender or age (Table 7). Furthermore, smell and taste disorders combined were present in 40.90% of VOTT+ patients. The severity of the disorder is anosmia and ageusia in 30% of the cases, while mild hyposmia and hypogeusia were observed in 59.25% of the cases. The olfactory disorder alone, was present as anosmia (12.12%), severe hyposmia 6.06%, mild hyposmia 25.75%, and moderate hyposmia (6.06%). It may be concluded from the analysis of the sample that the presence of both disorders is the prevailing clinical sign, and of those two, the most frequent olfactory disorder is mild hyposmia (32 patients). At the same time, anosmia was the second olfactory disorder in terms of frequency (17 patients). In contrast, hypogeusia as the only clinical sign is not frequent in coronavirus infection. Time Course of SARS-CoV-2 Grading by Means of VOT The assessment of chemosensory dysfunction as a function of time by means of the Venezuela olfactory test allowed to establish a group of subjects with anosmia 11/31 (35.48%) and another with mild hyposmia 15/31 (48.4%) on day 1. The number of individuals positive for mild hyposmia and normosmia in the VOT increased in frequency with time, as follows: day 5, 8/10 (80%); day 7, 17/19 (89.5%); day 10, 8/8 (100%); day 14 8/10 (80%); and day 20, 15/16 (93.75%). Between day 5 and day 20, the sense of smell of 66/142 (46.47%) subjects had been restored (normosmia), as evidenced by the VOT test. The average recovery interval was 8 to 10 days, with a

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

minimum of 3 days and a maximum of 20 (Figures 2A and 2B). Only one patient did not recover the sense of smell during the time of the study. Time Course of SARS-CoV-2 Grading by Means of RT-PCR Test The frequency analysis of the RT-PCR molecular test for SARS-CoV-2 was carried out for all individuals of the protocol in a systematic manner from day 1 to day 34 post infection. The viral gene expression was very frequent from day 1 to day 7, as it was present in 47/78 (60.25%) subjects; it decreased between day 10 and 14, and from day 16 to day 20, when it was evident in 15/78 (19.23%) and 11/78 (14.10%) subjects, respectively. Only 3 individuals had a positive RT-PCR test result on day 26 and only one did so until day 30. The frequency of VOTT+RT-PCR+ 66/275, and VOTT-RT-PCR+ 78/275 individuals is different from that of VOTT+RT-PCR-41/275, VOTT-RT-PCR- 90/275 subjects (Fisher's exact test P < 0.0184). The frequency of RT-PCR+ molecular tests is higher between days 1 and 14 and lower between day 16 and 24. It was observed that the maximum time interval for viral gene expression was 21 days (Figure 3). **DISCUSSION** The recent onset of this SARS-CoV-2 zoonosis in human populations has led to a significant number of studies aimed at understanding the variety of symptoms as part of the etiology of the disease. In the Venezuelan population, the time course of COVID19 has been lagging behind that of other countries, and this may have given time to establish treatment guidelines as a function of the expression of the disease. This study have evaluated the predictive value of a standardized smell test for the unbiased assessment of the sense of smell and taste in individuals with respect to a molecular diagnostic of SARS-CoV-2 infection by RT-PCR test. This is an original and innovative study, as it establishes in an objective and recurrent evaluation, by means of a smell test that is standardized for Venezuela and a classical taste test, the evolution of the chemosensory disorder of subjects until the sense of smell and taste are fully restored. Additionally, the viral genes analysis by means of the SARS-CoV-2 RT-PCR test and of the anti-coronavirus antibodies was carried out in symptomatic and asymptomatic patients until these had fully recovered. Clinical signs vary in patients with coronavirus infection, and the severity of the disease is determined by shortness of breath, oxygen saturation, pulmonary infiltrates, multiple organ failure, septic shock, and the need to use vasopressors, as defined by the National Institute of Health of the United States of America (NIH-USA SARS-

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

CoV-2 assessment guidelines). Anosmia and ageusia were otorhinolaryngological and neurological signs of the coronavirus disease. Currently, the physiopathology of anosmia due to COVID-19 is apparently better understood; however, there is still the question why patients with moderate to severe COVID-19 infection have less olfactory affectation. Findings of this study show that 98% of patients with smell and taste disorders had mild COVID19. These results are in agreement with a recent report of self-described olfactory dysfunction in mild forms of SARS-CoV-2 infection that did not require hospitalization (13). For instance, the chemosensory dysfunction established in this study by means of self-evaluation underestimates the incidence of this symptom; therefore it would be advisable to examine whether anosmia is less prevalent in more severe forms of the infection and, consequently, the mechanism that leads to the physiopathological process that gives rise to this affectation. The definition of a mild or severe form of SARS-CoV-2 infection may imply there is an immune response with more or less contention power thus leading to a milder or more serious viral infection, respectively. This response in the entryway of the virus may also imply that the progression of the infection depends on the time taken by the virus to move towards the upper or lower airways. Therefore, it is possible that, in the mild forms of the coronavirus infection, a more intense and faster immune response will produce more local inflammation that evolves into inflammatory processes involving the neuroepithelium and olfactory bulb. In contrast, in low intensity late immune responses, patients present with mild symptoms in ears, nose and throat; but later, these could also involve higher and lower airways with respiratory compromise (14, 15).These two hypotheses have not been experimentally corroborated, because results show that patients with severe or critical forms have a higher immunoglobulin concentration in the serum and nasal secretions than patients with mild forms; which additionally makes sense, because the severe respiratory compromise has been justified as being a cytokine storm mechanism. Since the beginning of the pandemic, COVID-19 symptoms reports have been about the respiratory tract affectation, with serious and fatal complications in a certain percentage of cases. The first reports involving a nervous system affectation were associated to a sudden decrease in the sense of smell, sometimes accompanied by a decrease in the sense of taste, which patients recovered from regardless whether they

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

had a positive infection outcome or not. Initial reports were based on telephone interviews or online self-assessments by means of a questionnaire. As a result, the incidence of the chemosensory disorder was 19.4% (2); 64% (16); and 85.6% (15). These findings confirmed the initial observation of Lechien et al. who were the first to mention the sudden loss of the sense of smell in SARS-CoV-2 infected patients. Subsequent reports expanded on the vision of this author and confirmed the association between the infection by this virus and the chemosensory disorder. Selfassessment of the senses of smell and taste has been proposed as an index of SARS-CoV-2 transmission that could be of value for projecting the need of hospital care units required for compromised patients (17). However, as it is commonly the case in these smell and taste self-assessment studies, sensitivity and specificity are compromised. Applying standardized tests to SARS-CoV-2 infected patients has allowed to determine the level of involvement of the sensory function in the progression of the viral pathology. In a previous study, an UPSIT test for the Persian population applied to a reduced number of patients in Iran established that the olfactory disorder is variable, as there was a reduced rate of anosmic subjects (25%), while the largest percentage had moderate and severe microsmia (60%). Therefore, it was suggested that this degree of sensitivity was not enough to be able to consider the smell test as an indicator of the progression of the infection (18). The senses of smell and taste form a physiological system that is affected by COVID-19; however, the degree of affectation seems to be mild. This has been shown by the studies carried out using as objective evaluator the chemosensory test of the Clinical Research Center of Connecticut, which has shown, just like Moein et al., findings, that a very small number were anosmic, while most had moderate and mild hyposmia (80%). At the same time, the taste test established that the taste affectation was mild to moderate. All patients maintained a normal degree of discrimination and a subjective overall recovery of 66%; but up to 88% presented with a certain degree of chemosensory disorder (19). In contrast with these results, in this study, the results of several smell and taste tests showed the progressiveness of the disorder and time to recover from the onset of the infection. Contrary to what was seen in prior studies, in our sample, mild hyposmia and anosmia accounted for the highest share with a progressive recovery. The onset of the infection and its evolution allowed to make an evaluation until the recovery of the

444

445

446

447

448

449

450

451

452

453

454

455

456

457458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

patient. Evidence of SARS-CoV-2 infection and its demonstration by virtue of new technologies have given rise to molecular tests with variable sensitivity and specificity. Findings suggesting an asymptomatic infection in significantly frequent cases of negative RT-PCR test results imply several possibilities, which include that individuals have either not been exposed to the infection or they received a reduced viral load. At the same time, the characteristics of the sample, as a result of collection, storage, preservation, and processing, could also contribute to the high number of negative results (20,21). The time course of the infection, and the effectiveness of molecular tests to prove the infection, suggest an order in the events of infection progression that range from 5 to 7 days for the first clinical signs to become evident. The sensitivity of the molecular diagnosis increases in a delayed manner, as a function of the increase in the concentration of viral particles that could reach a maximum level on the 7<sup>th</sup> day and up to the following 14 days, to then decrease gradually as a result of the immune response of the patient. In contrast, in this study, the RT-PCR molecular test leads to suggest a minimum time of 1 day from the date of admission of the patient to the protocol and up to 14 days. This is the first study that established a multiple system for following up the progression of the chemosensory disorder and detecting the infection; be it by means of the molecular test or the SARS-CoV-2-specific antibodies detection test. The Venezuelan olfactory test is a tool that has been validated taking into consideration the characteristics of the Venezuelan population. In this research, we corroborate the spontaneous recovery of most patients. Only one patient still has anosmia-type smell disorder; and in her case, other tests were carried out to establish the actual cause of such disorder. In this regard, there is similarity with what has been reported in the literature about recovery time. We did not find in our review of other investigations any relationship between the persistence of chemosensory dysfunction and the negativization of the RT-PCR test. Apparently, there is no relationship between the improvement of the disorder and the viral load detected by molecular and/or serologic tests. The presence of asymptomatic SARS-CoV-2 positive patients and the fact that the predictive value of the Venezuelan olfactory test and the basic taste test does not exceed 70% may be hypothetically explained, not only by the time when the

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

investigation began - which was too early with respect to the contagion peak in the country- but also by some social, demographic, and genetic characteristics of the sample studied. It could also be due to the virus mutations that affect certain populations. In this regard, the SARS-CoV-2 spike mutation has been described as mediating the infection in human cells. Korber et al. listed 13 mutations that are deemed to be within a wider phylogenetic spectrum that could change with geography and with time, and which could give some populations certain selective advantages as to the transmission or resistance to the infection. In the case of Europe, the spike mutation D614G was dominant and began spreading in February 2020 and had such aggressive impact on the population. There is evidence of recombinant strains circulating locally and that are indicative of infections by multiple strains (22). This is being researched currently in Colombia and Venezuela. Rodríguez-Morales et al. (23) described 3 genomic sequences of coronavirus mutations that may explain the behavior of the disease in Venezuela, in specific zones like Zulia, (where there has been significant migratory activity of people to and from Colombia and Brazil) and where the severity of the infection has been higher than in other geographic zones of the country (23). This hypothesis could explain why infections are mild or asymptomatic in some areas and severe in others, or why the penetrance of chemosensory dysfunction is lower than in other reports. We may conclude that there is significant presence of smell and taste disorders, as clinical signs, in the course of the mild coronavirus disease. Therefore, every patient who presents with symptoms, must be isolated and screened for the disease by means of appropriate diagnostic tests. Patients evolve towards the resolution of smell and taste disorders spontaneously and recover in a period of time between 3 days and 5 weeks, with an average of 8 to 10 days. Rapid diagnostic tests are not useful for diagnosing the coronavirus infection, but only for following it up. We would suggest including the olfactory test and taste test as part of the battery of tests complementary to the RT-PCR test for diagnosing SARS-CoV-2 and following up the progression of the disease. ACKNOWLEDGEMENTS Authors acknowledge to Physicians José M. García, Francis Sánchez, Isabel Duque, David Forero, Ptte Margarett Tovar, and Ptte María Barico. Altogether contributed supporting organization, and care of patients. Special mention goes to following

- 512 health Centres: Hospital Militar Universitario "Dr. Carlos Arvelo" (San Martín-
- 513 Caracas), Hospital "Dr. José Ignacio Baldó" (Algodonal-Caracas), Hospital General
- 514 "Dr. Jesús Yerena" (Lídice-Caracas), Hospital Oftalmológico "Dr. Francisco
- 515 Risquez" (Cotiza- Caracas), Hospital de los Seguros Sociales "Dr. Miguel Pérez
- 516 Carreño" (Caracas), Hospital de los Seguros Sociales "Dr. José María Vargas" (La
- 517 Guaira), Hospital Militar "Nelson Sayago Mora" (La Asunción-Nueva Esparta),
- 518 Hospital Militar "Dr. Vicente Salias" (Fuerte Tiuna-Caracas), Policlínica
- 519 Metropolitana (Estado Miranda), Hospital Clínico Universitario de Caracas.
- 520 Other case screening centers of the Health Department of the national Armed Forces
- 521 located in the Great Metropolitan Area of Caracas:
- 522 General Command of the Army and Aviation, 'Seguros Horizonte' headquarters,
- 523 Military Prosecution Department, TVFANB headquarters, National Armed Forces
- 524 Bank head office.

525

- 526 AUTHORSHIP CONTRIBUTION
- R. Pieruzzini, M Magris and C Ayala-Grosso, designed and performed the research.
- 528 R. Pieruzzini, JJ Navas, W Rodríguez, N Parra, E Luque, A Sánchez-Gago, S
- 529 González, A Hagobian, A Grullón, K Díaz, M Morales, M De Jesús, S Peña, L
- 530 Rodríguez, LL Peña, A Asaro, M Magris, performed research, C Ayala-Grosso, A
- Hagobian, M Magris, R Pieruzzini performed research and analyzed data; R.
- Pieruzzini, and C Ayala-Grosso revised, analyzed, and wrote the manuscript. R.
- Pieruzzini and C Ayala-Grosso equally contributed in analyzing data and wrote the
- manuscript.
- 535 CONFLICT OF INTEREST
- The authors of this investigation have no conflicts of interest to declare
- 537 FUNDING
- Resources for rapid tests and the virocult, as well as other supplies for sample
- collection and processing, were provided by the Ministry of the People's Power for
- Health of Venezuela.
- The disposable olfactory test kits were home-made and self-funded by the developers
- 542 of the VOT as follows: Wilneg Rodriguez, Carlos Velasquez and Rosalinda
- 543 Pieruzzini.

REFERENCES

545

- 1. Lechien JR, Chiesa-Estomba CM, De Siati DR et al.. Olfactory and gustatory
- dysfunctions as a clinical presentation of mild-to-moderate forms of the
- coronavirus disease (COVID-19): a multicenter European study. Eur Arch
- 550 Otorhinolaryngology 2020; 277(8):2251-2261.
- 551 2. Gane SB, Kelly C, Hopkins C. Isolated sudden onset anosmia in COVID-19
- infection. A novel syndrome? Rhinology 2020;58(3):299-301.
- 3. Ramanathan K, Antognini D, Combes A, et al. Planning and provision of ECMO
- services for severe ARDS during the COVID-19 pandemic and other outbreaks of
- emerging infectious diseases. Lancet Respir Med 2020;8(5):518-526.
- 556 4. Giacomelli A, Pagani G, Ridolfo AL, et al. Early administration of
- lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of
- SARS-CoV-2 infection: A retrospective cohort study. J Med Virol 2020;
- 559 10:10.1002/jmv.26407.
- 560 5. Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: An overview. J Chin
- Med Assoc 2020;83(3):217-220.
- 562 6. Brann DH, Tsukahara T, Weinreb C, et al. Non-neuronal expression of SARS-
- 563 CoV-2 entry genes in the olfactory system suggests mechanisms underlying
- 564 COVID-19-associated anosmia. Sci Adv 2020;6(31):eabc5801.
- 565 7. Netland J, Meyerholz DK, Moore S, et al. Severe acute respiratory syndrome
- coronavirus infection causes neuronal death in the absence of encephalitis in mice
- transgenic for human ACE2. J Virol 2008;82(15):7264-75.
- 8. Doty RL, Shaman P, Kimmelman CP, Dann MS. University of Pennsylvania
- Smell Identification Test: a rapid quantitative olfactory function test for the
- 570 clinic. Laryngoscope 1984;94(2 Pt 1):176-8.
- 9. Pieruzzini R, Rodríguez W, Velazquez C. Short Adaptation of the smell test of
- 572 the University of Pennsylvania (UPSIT) for the Venezuelan population.
- 573 medRxiv: <a href="https://medrxiv.org/cgi/content/short/2020.08.25.20182063v1">https://medrxiv.org/cgi/content/short/2020.08.25.20182063v1</a>
- 574 10. Hagobian A, Pieruzzini R. Test del Olfato Hospimil vs Test de Connecticut para
- 575 Diagnóstico de trastornos olfatorios. Acta Otorrinolaringológica 2020; 31(2):14-
- 576 20.
- 577 11. Castro L, Pieruzzini R, Luque E, Garcia L. Propuesta de un Test del gusto para la
- población Venezolana. Acta Otorrinolaringológica 2020; 31 (1):17-26.

- 579 12. Agresti, A. (2007). An Introduction to Categorical Data Analysis, 2nd ed. New
- York: John Wiley & Sons.
- 581 13. Yan CH, Faraji F, Prajapati DP, et al. Association of chemosensory dysfunction
- and COVID-19 in patients presenting with influenza-like symptoms. Int Forum
- 583 Allergy Rhinol. 2020; 10(7):806-813.
- 584 14. Saussez S, Lechien JR, Hopkins C. Anosmia: an evolution of our understanding
- of its importance in COVID-19 and what questions remain to be answered. Eur
- Arch Otorhinolaryngol. 2020; 9:1–5.
- 587 15. Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory
- dysfunctions as a clinical presentation of mild-to-moderate forms of the
- coronavirus disease (COVID-19): a multicenter European study. Eur Arch
- 590 Otorhinolaryngol. 2020; 277(8):2251-2261.
- 591 16. Spinato G, Fabbris C, Polesel J, et al. Alterations in Smell or Taste in Mildly
- 592 Symptomatic Outpatients With SARS-CoV-2 Infection. JAMA. 2020;
- 593 323(20):2089-2090.
- 594 17. Pierron D, Pereda-Loth V, Mantel M, et al. Smell and taste changes are early
- 595 indicators of the COVID-19 pandemic and political decision effectiveness. Nat
- 596 Commun. 2020;11(1):5152.
- 597 18. Moein ST, Hashemian SM, Mansourafshar B, et al. Smell dysfunction: a
- biomarker for COVID-19. Int Forum Allergy Rhinol. 2020; 10(8):944-950.
- 599 19. Vaira LA, Deiana G, Fois AG, et al. Objective evaluation of anosmia and ageusia
- in COVID-19 patients: Single-center experience on 72 cases. Head Neck. 2020;
- 601 42(6):1252-1258.
- 602 20. Kubina R, Dziedzic A. Molecular and Serological Tests for COVID-19 a
- 603 Comparative Review of SARS-CoV-2 Coronavirus Laboratory and Point-of-Care
- Diagnostics. Diagnostics (Basel). 2020; 10(6):434
- 605 21. Li Z, Yi Y, Luo X, Xiong N, et al. Development and clinical application of a
- 606 rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J
- 607 Med Virol. 2020; 10.1002/jmv.25727.
- 608 22. Korber B, Fischer WM, Gnanakaran S, et al. COVID-19 Genomics Group,
- McDanal C, Perez LG, Tang H, Moon-Walker A, Whelan SP, LaBranche CC,
- 610 Saphire EO, Montefiori DC. Tracking Changes in SARS-CoV-2 Spike: Evidence
- that D614G Increases Infectivity of the COVID-19 Virus. Cell. 2020; 182(4):812-
- 612 827.e19.

- 613 23. Rodriguez-Morales AJ, Balbin-Ramon GJ, Rabaan AA, et al. Genomic
- Epidemiology and its importance in the study of the COVID-19 pandemic. Infez
- 615 Med. 2020; 28(2):139-142.
- 616 **CORRESPONDING AUTHOR**
- 617 Rosalinda Pieruzzini MD
- 618 **Department of otorhinolaryngology.**
- 619 Unit of Neurorhinology
- 620 University Military Hospital "Dr. Carlos Arvelo".
- 621 San Martín- Caracas-Venezuela
- 622 rosalindapieruzzini@gmail.com
- 623 +58 424 1367083

624625626

Table 1. SARS-CoV-2 Group Definition					
Symptomatic with smell and	Symptomatic without smell	Asymptomatic			
taste dysfunction by VOT	and taste dysfunction by	(ASyM)			
(SyMVOTT+)	VOT				
	(SyMVOTT-)				
N=107	N= 61	N=107			
Subjects with general symptoms	Subjects with general	Patients who did not present with			
as described below:	symptoms as described	any prior symptoms or signs			
headache, cough, fever, general	below:	associated with the coronavirus.			
malaise, chest pain, dyspnea,	headache, cough, fever,				
myalgia, arthralgia, shivering,	general malaise, chest pain,				
hyporexia, nausea, vomiting,	dyspnea, myalgia, arthralgia,				
diarrhea and any other symptom	shivering, hyporexia, nausea,				
described in the literature that	vomiting, diarrhea and any				
might be present and/or suggest	other symptom described in				
a SARS-CoV-2 infection and	the literature that might be				
positive smell and taste results	present and/or suggest a				
according to the VOT* rating	SARS-CoV-2 infection				
and positive smell and taste					
results in the VOT grading					
VOT: Venezuelan Olfactory Test					

Table 2. Distribution by Age and Gender						
	Males			Females		
	151			124		
Age Range	N	%	N	%		
18-24	27	9.81	16	5.81		

631632

633

634

635

636

25-31	41	14.90	32	11.63
32-38	31	11.27	28	10.18
39-45	15	5.45	19	6.90
46-52	16	5.81	9	3.27
53-59	17	6.18	10	3.63
60-66	4	1.45	10	3.63

Table 3. PCR and PDR Testing PCR-PCR+ PCR+ PCR+ PCR-PCR-/PDR+ /PDR-/PDR-/PDR+ N=131 N=144% % SyVOTT+ 16 50 66 45.83 38 3 41 31.30 SyVOTT-14 20 34 23.61 24 3 27 20.61 **ASyM** 27 38 25 17 44 30.55 48.10 63  $X^2 = 9.19$ , gl = 2, p < 0.05

Tabla 3.1 Standardized Residuals for Presence or Absence of Symptoms and SARS-CoV-2 Infection					
Presence of Symptoms PCR+ PCR-					
SyVOTT+	2.56*	-2.56*			
SyVOTT-	0.37	-0.37			
ASYM	-2.88*	2.88*			
*p < 0.05					

 Table 4. Predictive Value of VOT and PCR for Diagnosing SARS-CoV-2 Infection

 RT-PCR+
 RT-PCR 

 N= 144
 N= 131

 SyVOTT+
 66
 41

 ASyM + SyVOTT 78
 90

  $X^2$  13.796, gl = 2, P <0.05</td>

Table 5. Association between Clinical Grading of SARS-CoV-2 Disease and a Positive Venezuelan Olfactory Test and Taste Test (VOTT+)

Clinical Grading of COVID-19 Disease VOTT+ (N=66)

Mild 65 (98.48%)

Moderate 1 (1.51%)

Severe 0

Critical 0

Table 6. General Symptoms and Chemosensory Dysfunction in SARS-CoV-2 Infection					
	RT-PCR+ Standardized Residuals				
	N= 97	%			
VOT+	18	18.6	-3.14*		
SyVOTT+	48	43.9	-3.28*		
SyVOTT-	32	37.8	-0.14		

 $X^2=13.796$ , gl=2, p<0.01. Chi Square Test  $X^2=13.796$ , gl=2, p<=0.01. \* Standardized Residuals significant values p<0.05. It is worth mentioning that the analysis shown in this table was carried out with all the patients that had symptoms associated with COVID-19 (97/144 positive cases) excluding asymptomatic cases (44/144).

	T	able 7. VOT+	and taste + by	Age and Gene	der		
	Males				Females		
	Age Range (years old)			Ag	Age Range (years old)		
	18-35	36-51	>52	18-35	36-51	>52	
VOTT*	%				%		
Anosmic	0	3.0	1.5	1.5	3.0	3.0	
Mild	7.6	1.5	1.5	7.6	6.1	1.5	
Hyposmia							
Moderate	3.0	0	0	1.5	0	1.5	
Hyposmia							
Severe	1.5	0	0	1.5	3.0	0	
Hyposmia							
Hypogeusia	6.5	0	1.5	1.5	0	0	
Both	7.6	6.0	4.5	13.6	3.0	6.1	
VOTT* : Vene	zuelan Olfact	ory Test and	Taste Grading				

## Legends

Figure 1. Time course of number of cases RT-PCR+ and RT-PCR- along months of COVID19.

The broken line represents the patients with smell and taste disorders who were positive for COVID-19 by PCR-RT. An increase is observed since May with a maximum in July-August. The solid line represents patients with chemosensory disorders without being positive for COVID-19.

Figure 2. Olfactory impairment and evolution of SARS-CoV-2 infection. Venezuelan

651 Olfactory Test was performed until Olfactory Index Grading reached normosmic 652 value (8-10). A. Each bar represents number of subjects at specific grade of olfaction. 653 Bar symbol represents day of testing (Day 1 -10). B. Each bar represents number of 654 subjects at specific grade of olfaction. Bar symbol represents day of testing (Day 12 -655 20) 656 657 Figure 3. Evolution of RT-PCR molecular analisis under SARS-CoV-2 infection. 658 RT-PCR molecular analysis was performed multiple times to each patient until 659 testing become negative. Each bar represent the number of patients RT-PCR+ 660 (black) and RT-PCR- (white) through time (days of PCR testing). 661 662




Figure 1




Figure 2




Figure 3A




Figure 3B